Anticancer Bioscience
  • About
    • Management Team
    • Scientific Advisory Board
  • Pipeline
  • Science
    • SYMPLEX
    • Publications
  • News & Events
    • Press Releases
    • In the News
  • Careers
  • Contact

Press release

31 December 2025
Anticancer Bioscience Reports RMB 80 Million Financing to Support JMBI-001 Clinical Development

Chengdu, China, December 31, 2025 — Anticancer Bioscience (ACB), a biotechnology company developing cancer therapies that exploit MYC synthetic lethality, secured RMB 80 million in financing on December 31, 2025. The proceeds were intended primarily to support IND-enabling studies and Phase 1 and Phase 2 clinical trials of JMBI-001, the company’s lead investigational drug candidate.

JMBI-001 is an oral small-molecule drug candidate designed to exploit cellular dependencies associated with deregulated MYC activity in cancer. Preclinical studies have demonstrated antitumor activity across multiple tumor models, as well as antiangiogenic effects and treatment-induced antitumor immune responses.

The clinical trials will evaluate JMBI-001’s safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity. The resulting data will inform dose selection and subsequent clinical development decisions.

About Anticancer Bioscience

Anticancer Bioscience (ACB) is a Chengdu-based biotechnology company developing innovative anticancer therapies that exploit cancer-specific dependencies. Its drug-development programs translate discoveries in cancer biology and synthetic lethality into novel therapeutic approaches.


Anticancer Bioscience © 2026
Terms of use
Privacy policy